Mixed Phase III results for Sucampo's lubiprostone in opioid-related bowel dysfunction
This article was originally published in Scrip
Sucampo Pharmaceuticals has reported mixed top-line results from two Phase III trials with its gastrointestinal product lubiprostone for the management of opioid-induced bowel (OBD) dysfunction in patients with chronic, non-cancer pain.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.